Fatigue, Inflammation, and ω-3 and ω-6 Fatty Acid Intake Among Breast Cancer Survivors
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Purpose: Evidence suggests that inflammation may drive fatigue in cancer survivors. Research in healthy populations has shown reduced inflammation with higher dietary intake of ω-3 polyunsaturated fatty acids (PUFAs), which could potentially reduce fatigue. This study investigated fatigue, inflammation, and intake of ω-3 and ω-6 PUFAs among breast cancer survivors. Methods: Six hundred thirty-three survivors (mean age, 56 years; stage I to IIIA) participating in the Health, Eating, Activity, and Lifestyle Study completed a food frequency/dietary supplement questionnaire and provided a blood sample assayed for C-reactive protein (CRP) and serum amyloid A (30 months after diagnosis) and completed the Piper Fatigue Scale and Short Form-36 (SF-36) vitality scale (39 months after diagnosis). Analysis of covariance and logistic regression models tested relationships between inflammation and fatigue, inflammation and ω-3 and ω-6 PUFA intake, and PUFA intake and fatigue, controlling for three incremental levels of confounders. Fatigue was analyzed continuously (Piper scales) and dichotomously (SF-36 vitality ≤ 50). Results: Behavioral (P = .003) and sensory (P = .001) fatigue scale scores were higher by increasing CRP tertile; relationships were attenuated after adjustment for medication use and comorbidity. Survivors with high CRP had 1.8 times greater odds of fatigue after full adjustment (P < .05). Higher intake of ω-6 relative to ω-3 PUFAs was associated with greater CRP (P = .01 after full adjustment) and greater odds of fatigue (odds ratio, 2.6 for the highest v lowest intake; P < .05). Conclusion: Results link higher intake of ω-3 PUFAs, decreased inflammation, and decreased physical aspects of fatigue. Future studies should test whether ω-3 supplementation may reduce fatigue among significantly fatigued breast cancer survivors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513 · cited 1×
“0 mg/L).(47) ANCOVA models tested differences in CRP and SAA levels by subgroup of -3 and -6 intake.”
MethodFatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.
Bower, J. E., Ganz, P. A., Desmond, K. A., Rowland, J. H., Meyerowitz, B. E., & Belin, T. R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.743 · Cited by 1,134 · cited 1×
“Dichotomous fatigue was assessed using the vitality subscale of the Short Form-36 (SF-36)(39) (0 to 100 scale; lower scores indicate higher fatigue); women with vitality scores of 50 and lower were classified as fatigued.(7) Inflammatory markers.”
MethodRelationship of plasma polyunsaturated fatty acids to circulating inflammatory markers.
Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F., Martin, A., Andres-Lacueva, C., Senin, U., & Guralnik, J. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1303 · Cited by 696 · cited 2×
“A higher -6: -3 ratio has been related to higher levels of proinflammatory markers (IL-6, IL-1 receptor antagonist, TNF- , and CRP)(18,23) and lower levels of anti-inflammatory markers (IL-10 and transforming growth factor ).(18) The -6: -3 ratio may be a stronger predictor of inflammation than either fatty acid alone.”
BackgroundO’Connor, M.-F., Bower, J. E., Cho, H. J., Creswell, J. D., Dimitrov, S., Hamby, M. E., Hoyt, M. A., Martin, J. L., Robles, T. F., Sloan, E. K., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.04.005 · Cited by 500 · cited 1×
“Overadjustment for factors including those likely to be mediators can lead to bias and erroneous conclusions.(48,49) To evaluate potential bias, three incrementally adjusted models were run for each set of analyses, adjusting for age, race/study site, tamoxifen use, and menopausal status (model 1); model 1 plus antide…”
BackgroundInflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer
Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., Cole, S., & Aziz, N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2584 · Cited by 315
Endres, S., Meydani, S. N., Ghorbani, R., Schindler, R., & Dinarello, C. A. (1993) · Journal of Leukocyte Biology · doi:10.1002/jlb.54.6.599 · Cited by 228
Kalogeropoulos, N., Panagiotakos, D. B., Pitsavos, C., Chrysohoou, C., Rousinou, G., Toutouza, M., & Stefanadis, C. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.01.023 · Cited by 160 · cited 1×
“The -6: -3 ratio may be a stronger predictor of inflammation than either fatty acid alone.(23) Supplementing healthy people with -3 PUFAs, especially long-chain -3 PUFAs, can reduce inflammation by suppressing synthesis of IL-1 , IL-1 , IL-2, and TNF- .”
Background
Research works printed but not linked: 51
- 10.1097/00000446-200603003-00025 · DOI
- 10.1093/jncimonographs/lgh027 · DOI · Paper page
- 10.1002/cncr.21671 · DOI · Paper page
- 10.1188/04.ONF.591-598 · DOI · Paper page
- Stepanski EJ, 2009, J Clin Sleep Med, 5, 132, 10.5664/jcsm.27441 · DOI
- 10.1634/theoncologist.12-S1-35 · DOI · Paper page
- 10.1016/j.ejca.2008.09.010 · DOI · Paper page
- 10.1016/j.soncn.2007.01.004 · DOI
- 10.1634/theoncologist.5-5-353 · DOI · Paper page
- 10.1016/j.bbi.2006.11.004 · DOI · Paper page
- 10.1200/JCO.2007.10.7805 · DOI · Paper page
- 10.1159/000079408 · DOI · Paper page
- 10.1158/1078-0432.CCR-05-2398 · DOI · Paper page
- 10.1002/cncr.11382 · DOI · Paper page
- 10.1016/j.bbi.2010.09.010 · DOI · Paper page
- 10.1038/ejcn.2009.20 · DOI
- 10.3945/ajcn.2009.28820 · DOI
- 10.1016/j.nutres.2008.03.008 · DOI
- 10.1016/j.amjcard.2009.01.016 · DOI · Paper page
- 10.1016/S0002-9149(01)02049-5 · DOI
- 10.1016/j.atherosclerosis.2008.12.013 · DOI · Paper page
- 10.1056/NEJM198902023200501 · DOI · Paper page
- 10.1093/ajcn/63.1.116 · DOI · Paper page
- 10.1093/jn/121.4.547 · DOI · Paper page
- 10.1007/s11695-007-9062-x · DOI
- 10.1093/jn/129.6.1120 · DOI
- 10.1016/j.nut.2005.03.001 · DOI
- 10.1080/01635580701365068 · DOI · Paper page
- 10.3748/wjg.14.2434 · DOI · Paper page
- 10.1200/JCO.2003.07.057 · DOI · Paper page
- 10.1016/S1047-2797(01)00274-5 · DOI
- 10.1002/ijc.20072 · DOI
- Piper BF, 1998, Oncol Nurs Forum, 25, 677
- Ware JE, 1992, Conceptual framework and item selection. Med Care, 30, 473
- 10.1249/MSS.0b013e31819c7feb · DOI · Paper page
- 10.1016/S1047-2797(98)00055-6 · DOI · Paper page
- 10.1007/s10549-007-9834-y · DOI
- 10.1002/dmr.5610080404 · DOI
- Pereira MA, 1997, Med Sci Sports Exerc, 29, S1, 10.1097/00005768-199705001-01074 · DOI · Paper page
- 10.1073/pnas.0610362104 · DOI · Paper page
- 10.1111/j.1527-3466.2006.00033.x · DOI · Paper page
- 10.1016/j.bbi.2009.05.053 · DOI
- Wener MH, 2000, J Rheumatol, 27, 2351
- 10.1016/j.clinthera.2007.02.006 · DOI
- 10.1200/JCO.2008.18.9068 · DOI · Paper page
- 10.1017/S0954422408998620 · DOI · Paper page
- 10.1161/01.HYP.0000145292.38579.f4 · DOI
- Maes M, 2005, Neuro Endocrinol Lett, 26, 745
- 10.1592/phco.27.5.633 · DOI
- 10.1007/s10549-008-9985-5 · DOI
- 10.1016/S0022-1759(98)00057-X · DOI
Cited by
Cancer-related fatigue—mechanisms, risk factors, and treatments
Bower, J. E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.127 · Cited by 1,666
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Functional Roles of Fatty Acids and Their Effects on Human Health
Calder, P. C. (2015) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607115595980 · Cited by 1,160
Stark, K. D., Van Elswyk, M. E., Higgins, M. R., Weatherford, C. A., & Salem, N. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.05.001 · Cited by 519
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“Several epidemiologic and observational studies report that subjects with higher n-3 LC-PUFA levels in blood have lower proinflammatory cytokine production (Ferrucci et al., 2006; KiecoltGlaser et al., 2007, 2011; Farzaneh-Far et al., 2009; Alfano et al., 2012).”
Background
Metadata
- Authors
- Alfano, C. M., Imayama, I., Neuhouser, M. L., Kiecolt-Glaser, J. K., Smith, A. W., Meeske, K., McTiernan, A., Bernstein, L., Baumgartner, K. B., Ulrich, C. M., & Ballard-Barbash, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-04-20
- Volume
- 30
- Issue
- 12
- Pages
- 1280-1287
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123963828
- Cited by
- 152
- References
- 8
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatigue, Inflammation, and ω-3 and ω-6 Fatty Acid Intake Among Breast Cancer Survivors. https://app.cochat.ai/papers/10.1200/jco.2011.36.4109
- The paper
- Alfano, C. M., Imayama, I., Neuhouser, M. L., Kiecolt-Glaser, J. K., Smith, A. W., Meeske, K., McTiernan, A., Bernstein, L., Baumgartner, K. B., Ulrich, C. M., & Ballard-Barbash, R. (2012). Fatigue, Inflammation, and ω-3 and ω-6 Fatty Acid Intake Among Breast Cancer Survivors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.36.4109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.